Table I.
Patient characteristics with respect to treatment.
| Treatment arm | ||
|---|---|---|
| Characteristic | Arm A (EB) | Arm B (PGB) |
| Total patients, n | 46 | 58 |
| Age, years (range) | 61.2 (40–85) | 59.8 (41–83) |
| Sex | ||
| Male | 26 (56.5) | 34 (58.6) |
| Female | 20 (43.5) | 24 (41.4) |
| ECOG performance status | ||
| 0 | 25 (54.3) | 30 (51.7) |
| 1 | 19 (41.3) | 27 (46.6) |
| 2 | 2 (4.3) | 1 (1.7) |
| UICC stage | ||
| IIIB | 3 (6.5) | 10 (17.2) |
| IV | 43 (93.5) | 48 (82.8) |
| Histology | ||
| Adenocarcinoma | 40 (87.0) | 54 (93.1) |
| Large cell | 2 (4.3) | 2 (3.4) |
| Not specified | 4 (8.7) | 2 (3.4) |
| Smoking status | 1 (2.2) | 2 (3.4) |
| Missing | ||
| Current smoker | 14 (30.4) | 18 (31.0) |
| Former light smoker | 1 (2.2) | 4 (6.9) |
| Former smoker | 19 (41.3) | 22 (37.9) |
| Never smoked | 11 (23.9) | 12 (20.7) |
| EGFR mutation status | 3 (6.5) | 2 (3.4) |
| Missing | ||
| Mutation | 8 (17.4) | 7 (12.1) |
| Wild type | 35 (76.1) | 49 (84.5) |
| E-cadherin immunoreactivity | 1 (2.2) | 1 (1.7) |
| Missing | ||
| <8 | 24 (52.2) | 30 (51.7) |
| ≥8 | 21 (45.7) | 27 (46.6) |
| Vimentin immunoreactivity | 3 (6.5) | 0 (0) |
| Missing | ||
| 0 | 32 (69.9) | 35 (60.3) |
| >0 | 11 (23.9) | 23 (39.7) |
Data are presented as n, mean (range) or n (%). EB, erlotinib/bevacizumab; PGB, cisplatin/gemcitabine/bevacizumab; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; UICC, Union for International Cancer Control; ECOG, Eastern Cooperative Oncology Group.